Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Acknowledgment of Support
This activity is supported by educational grants from Janssen Scientific Affairs, LLC; Pharmacyclics LLC, an AbbVie Company; and Seagen Inc.
Mentors in Medicine Series on Applied Precision Medicine: Focus on Molecular Markers That Guide Treatment Options in Mantle Cell Lymphoma
Release Date: May 27, 2021
Expiration Date: May 27, 2022
Activity Overview
Mentors in Medicine Series on Applied Precision Medicine: Focus on Molecular Markers That Guide Treatment Options in Mantle Cell Lymphoma is a CME-certified, case-based, live webcast. This educational activity will provide practicing oncologists with expert perspectives on incorporating biomarker testing into everyday clinical practice to determine diagnosis and inform treatment selection for their patients with mantle cell lymphoma. Renowned faculty will analyze recent clinical trial evidence to optimize therapeutic strategies, using real patient cases as a starting point. Each case will include an expert analysis of Show Me the Data® as well as Key Takeaways 4 Tomorrow that can be applied immediately in the oncology clinical practice.
This educational activity is an archive of the live virtual webcast held on May 20, 2021.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Janssen Scientific Affairs, LLC; Pharmacyclics LLC, an AbbVie Company; and Seagen Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational program is intended for hematologists and oncologists involved in the treatment of patients with mantle cell lymphoma. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of patients with mantle cell lymphoma are also invited to attend.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate biomarker testing into diagnosis and/or therapy selection for treatment of patients with mantle cell lymphoma
- Analyze recent data on the efficacy and safety of therapeutic options for the treatment of patients with mantle cell lymphoma
- Apply optimal management strategies in the treatment of patients with mantle cell lymphoma based on recent clinical trial findings
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Series Chair & Moderator
Physician-in-Chief, Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer, John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology, Hackensack Meridian School of Medicine
Professor of Medicine, Georgetown University
Hackensack, NJ
Disclosures: Grant/Research Support: PI: Acerta Pharma, AstraZeneca, Celgene Corporation, Constellation Pharmaceuticals, Genentech/Hoffmann-La Roche, Infinity Pharmaceuticals, Infinity Pharmaceuticals/Verastem Oncology, Janssen Pharmaceuticals, Karyopharm, Kite, Pharmacyclics; Consultant: Acerta Pharma, Celgene Corporation, Gilead Sciences, Janssen Pharmaceuticals, Kite, Xcenda; Stock/Shareholder: COTA; Other: Honoraria: AstraZeneca, Celgene Corporation, Gilead Sciences, Kite, Xcenda; Advisory: AstraZeneca, COTA, Elsevier’s PracticeUpdate, Gilead Sciences, Janssen Pharmaceuticals, Kite.
Faculty
Director, Lymphoma Program
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St. Louis, MO
Disclosures: Grant/Research Support: AbbVie, Acerta Pharma, AstraZeneca, BeiGene, Celgene, Genentech, Janssen, Karyopharm, Kite, MEI Pharma, MorphoSys Pharmacyclics, Roche.
Puddin Clarke Endowed Professor
Department of Lymphoma and Myeloma
MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: Acerta Pharma, AstraZeneca, BeiGene, BioInvent, InnoCare, Janssen, Juno Therapeutics, Kite, Lilly, Loxo Oncology, Molecular Templates, Oncternal Therapeutics, Pharmacyclics, VelosBio; Consultant: AstraZeneca, Bayer Healthcare, CStone, Genentech, Janssen, Juno Therapeutics, Loxo Oncology, Oncternal Therapeutics, Pharmacyclics, VelosBio; Speakers’ Bureau: Anticancer Association of Hunan, Clinical Care Options, Guangdong Precision Medicine Application Association, Hebei Cancer Prevention Federation, Janssen, Mumbai Hematology Group, NewBridge Pharmaceuticals.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
